E7070

E7070 is an experimental drug that is being studied for the treatment of cancer. It belongs to the family of drugs called sulfonamides.

Overview

E7070 is a synthetic sulfonamide with potential antineoplastic activity. E7070 inhibits cell cycle progression at the G1 phase and the G1/S transition, which may result in the inhibition of tumor cell proliferation and tumor growth.

Mechanism of Action

E7070 inhibits the cell cycle by blocking the transition from the G1 phase to the S phase. This is achieved by inhibiting the activity of cyclin-dependent kinases (CDKs), which are essential for cell cycle progression. By blocking the activity of CDKs, E7070 prevents the synthesis of DNA and the proliferation of tumor cells.

Clinical Trials

E7070 has been studied in several clinical trials for the treatment of various types of cancer, including colorectal cancer, lung cancer, and breast cancer. The results of these trials have shown that E7070 has potential as a cancer treatment, but further research is needed to confirm these findings.

Side Effects

As with all chemotherapy drugs, E7070 can cause side effects. These may include nausea, vomiting, diarrhea, and fatigue. It is important for patients to discuss these potential side effects with their healthcare provider before starting treatment with E7070.

See Also

• Sulfonamides
• Antineoplastic
• Cell cycle
• Tumor cell
• Cyclin-dependent kinases
• Clinical trials
• Chemotherapy

E7070 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia